A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults with Moderate to Severe Chronic Spontaneous Urticaria.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518786-10-01

Acronym

EVO756-CSU001

Enrollment

Registered

2025-06-19

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to Severe Chronic Spontaneous Urticaria

Brief summary

Mean change from baseline in UAS7 at Week 12

Detailed description

Percent change from baseline in UAS7 at Week 12, Mean and percent change from baseline in UAS7 at Weeks 1, 2, 4, 8, Mean and percent change from baseline in ISS7 at Weeks 1, 2, 4, 8, 12, Mean and percent change from baseline in HSS7 at Weeks 1, 2, 4, 8, 12, Mean and percent change from baseline in AAS7 at Weeks 1, 2, 4, 8, 12, Proportion of subjects achieving UAS7 ≤ 6 and UAS7 = 0

Interventions

DRUGEVO756 Potassium

DRUGPLACEBO

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Mean change from baseline in UAS7 at Week 12	—

Secondary

Measure	Time frame
Percent change from baseline in UAS7 at Week 12, Mean and percent change from baseline in UAS7 at Weeks 1, 2, 4, 8, Mean and percent change from baseline in ISS7 at Weeks 1, 2, 4, 8, 12, Mean and percent change from baseline in HSS7 at Weeks 1, 2, 4, 8, 12, Mean and percent change from baseline in AAS7 at Weeks 1, 2, 4, 8, 12, Proportion of subjects achieving UAS7 ≤ 6 and UAS7 = 0	—

Countries

Bulgaria, Germany, Hungary, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026